Home > Search Results
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 1 to 20 of 169

Are antenatal weight management interventions effective in preventing pre-eclampsia? Systematic review of randomised control trials

Bibliographic details: Ho LC, Saunders KA, Owen DJ, Ibrahim UN, Bhattacharya S.  Are antenatal weight management interventions effective in preventing pre-eclampsia? Systematic review of randomised control trials. Pregnancy Hypertension 2012; 2(4): 341-349 Available from: http://www.pregnancyhypertension.org/article/S2210-7789%2812%2900016-5/abstract

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Accuracy of fibronectin tests for the prediction of pre-eclampsia: a systematic review

The review assessed the accuracy of plasma fibronectin in predicting pre-eclampsia. It was generally well-conducted and well-reported, but the available data were limited and the index test, diagnostic threshold and definition of pre-eclampsia varied between the studies. The authors concluded that fibronectin shows promise but more research is required; this is a reasonable conclusion for the limited data available.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2007

Accuracy of mean arterial pressure and blood pressure measurements in predicting pre-eclampsia: systematic review and meta-analysis

This review concluded that when blood-pressure is measured in the first or second trimester, the mean arterial pressure is a better predictor for pre-eclampsia than systolic or diastolic blood-pressure, or an increased blood-pressure. The authors acknowledged the limitations of the evidence available. However, this was a generally well-conducted review and the results seem reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

Periodontal disease and pre-eclampsia: a systematic review

AIM: This review evaluates the possible relationship between periodontal disease and pre-eclampsia, a major pregnancy complication. A generalized inflammatory response plays an important role in the pathogenesis of pre-eclampsia. Because periodontal disease is a low-grade inflammatory state, periodontal disease might contribute to the pathogenesis of pre-eclampsia.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2010

Meta-analysis of the methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to pre-eclampsia

A number of studies have investigated the association between the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and the risk of pre-eclampsia (PE) in various populations and have delivered inconsistent results. Therefore, this meta-analysis of 36 case-control studies, comprising 4253 PE cases and 4950 controls, were assessed to evaluate a possible association. The pooled results showed that the MTHFR C677T polymorphism was significantly associated with PE (P=0.03, odds ratio (OR)=1.25, 95% confidence interval (CI)=1.02-1.54, for the additive comparison; P=0.04, OR=1.14, 95% CI=1.01-1.29, for the dominant genetic model). The results of the subgroup analysis showed that MTHFR 677T had the effect of increasing the PE risk for the recessive genetic model (P<0.0001, OR=1.76, 95% CI=1.33-2.33, P(heterogeneity)=0.28), the additive comparison (P=0.002, OR=2.09, 95% CI=1.31-3.31, P(heterogeneity)=0.08) and allele contrasts (P=0.03, OR=1.42, 95% CI=1.04-1.95, P(heterogeneity)=0.0001) in the Asians, while no evidence of an association between MTHFR C677T polymorphisms and PE was observed in the Caucasians. This meta-analysis suggests that the MTHFR C677T polymorphism is capable of causing PE susceptibility in the Asians but not in the Caucasians.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

The role of L-arginine in the prevention and treatment of pre-eclampsia: a systematic review of randomised trials

Pre-eclampsia is a significant health issue in pregnancy, complicating between 2-8% of pregnancies. L-arginine is an important mediator of vasodilation with a potential preventative role in pregnancy related hypertensive diseases. We aimed to systematically review randomised trials in the literature assessing the role of L-arginine in prevention and treatment of pre-eclampsia. We searched the Cochrane Controlled Trials Register, PUBMED, and the Australian and International Clinical Trials Registry, to identify randomised trials involving pregnant women where L-arginine was administered for pre-eclampsia to improve maternal and infant health outcomes. We identified eight randomised trials, seven of which were included. The methodological quality was fair, with a combined sample size of 884 women. For women at risk of pre-eclampsia, L-arginine was associated with a reduction in pre-eclampsia (RR: 0.34, 95% CI: 0.21-0.55), when compared with placebo and a reduction in risk of preterm birth (RR: 0.48 and 95% CI: 0.28 to 0.81). For women with established hypertensive disease, L-arginine was associated with a reduction in pre-eclampsia (RR: 0.21; 95% CI: 0.05-0.98). L-arginine may have a role in the prevention and/or treatment of pre-eclampsia. Further well-designed and adequately powered trials are warranted, both in women at risk of pre-eclampsia and in women with established disease.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data

This review of individual patient data evaluated the efficacy of antiplatelet agents for the primary prevention of pre-eclampsia. Antiplatelet agent prophylaxis reduced the risk of pre-eclampsia, pre-term birth before 34 weeks' gestation and serious adverse outcomes of pregnancy, without increasing the rate of bleeding events. The review conclusions are likely to be reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2007

Plasma volume expansion for treatment of preeclampsia

Not enough evidence to show the effects of plasma volume expansion for women with preeclampsia.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2010

Association between the SERPINE1 (PAI-1) 4G/5G insertion/deletion promoter polymorphism (rs1799889) and pre-eclampsia: a systematic review and meta-analysis

The SERPINE1 -675 4G/5G promoter region insertion/deletion polymorphism (rs1799889) has been implicated in the pathogenesis of pre-eclampsia (PE), but the genetic association has been inconsistently replicated. To derive a more precise estimate of the association, a systematic review and meta-analysis was conducted. This study conformed to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed (MEDLINE), Scopus and HuGE Literature Finder literature databases were systematically searched for relevant studies. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for the allelic comparison (4G versus 5G) and genotypic comparisons following the co-dominant (4G/4G versus 5G/5G and 4G/5G versus 5G/5G), dominant (4G/4G+4G/5G versus 5G/5G) and recessive (4G/4G versus 4G/5G+5G/5G) genetic models. Between-study heterogeneity was quantified by I(2) statistics and publication bias was appraised with funnel plots. Sensitivity analysis was conducted to evaluate the robustness of meta-analysis findings. Meta-analysis of 11 studies involving 1297 PE cases and 1791 controls found a significant association between the SERPINE1 -675 4G/5G polymorphism and PE for the recessive genetic model (OR = 1.36, 95% CI: 1.13-1.64, P = 0.001), a robust finding according to sensitivity analysis. A low level of between-study heterogeneity was detected (I(2) = 20%) in this comparison, which may be explained by ethnic differences. Funnel plot inspection did not reveal evidence of publication bias. In conclusion, this study provides a comprehensive examination of the available literature on the association between SERPINE1 -675 4G/5G and PE. Meta-analysis results support this polymorphism as a likely susceptibility variant for PE.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review

BACKGROUND AND AIMS: Excessive generation of plasminogen activator inhibitor-type 1 (PAI-1) is implicated in the pathogenesis of pre-eclampsia and related conditions. The PAI-1 (-675 4G/5G) promoter polymorphism (rs1799889) affects transcriptional activity and is a putative genetic risk factor for pre-eclampsia. The aim of this study was identify, appraise and synthesise the available evidence for the association of the PAI-1 (-675 4G/5G) polymorphism with pre-eclampsia.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Pre-eclampsia is associated with, and preceded by, hypertriglyceridaemia: a meta-analysis

BACKGROUND: Elevated triglycerides are a feature of the metabolic syndrome, maternal obesity, maternal vasculitis (i.e. systemic lupus erythematosus) and diabetes mellitus. These conditions are all known risk factors for pre-eclampsia. Hypertriglyceridaemia therefore may be associated with pre-eclampsia and indeed this may precede the presence of overt disease.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis

This review found that Doppler ultrasonography was a better predictor of pre-eclampsia than of intrauterine growth restriction; pulsatility index, alone or combined with notching, in the second trimester was the most predictive Doppler index. In addition to other limitations, most of the authors? conclusions were based on results from single studies so cannot be considered reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2008

Altered dietary salt for preventing preeclampsia, and its complications

Low salt intake in pregnancy is unlikely to prevent preeclampsia.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2012

An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management

BACKGROUND: Pre-eclampsia/eclampsia is one of the most common causes of maternal and perinatal morbidity and mortality in low and middle income countries. Magnesium sulfate is the drug of choice for prevention of seizures as part of comprehensive management of the disease. Despite the compelling evidence for the effectiveness of magnesium sulfate, concern has been expressed about its safety and potential for toxicity, particularly among providers in low- and middle-income countries. The purpose of this review was to determine whether the literature published in these global settings supports the concerns about the safety of use of magnesium sulfate.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Estimation of proteinuria as a predictor of complications of pre-eclampsia: a systematic review

The authors concluded that testing for proteinuria was a poor predictor of major maternal and foetal complications in women with pre-eclampsia. There were some methodological concerns in the review process and the synthesis of apparently clinically heterogeneous studies. Therefore, the extent to which the authors' conclusion is reliable is unclear.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Accuracy of body mass index in predicting pre-eclampsia: bivariate meta-analysis

OBJECTIVE: The objective of this study was to determine the accuracy of body mass index (BMI) (pre-pregnancy or at booking) in predicting pre-eclampsia and to explore its potential for clinical application.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2007

Low-dose calcium supplementation for preventing pre-eclampsia: a systematic review and commentary

BACKGROUND: Epidemiological data link low dietary calcium with pre-eclampsia. Current recommendations are for 1.5-2 g/day calcium supplementation for low-intake pregnant women, based on randomised controlled trials of ≥1 g/day calcium supplementation from 20 weeks of gestation. This is problematic logistically in low-resource settings; excessive calcium may be harmful; and 20 weeks may be too late to alter outcomes.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis

BACKGROUND: Biomarkers have been proposed for identification of women at increased risk of developing pre-eclampsia.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Low‐dose dopamine for women with severe preeclampsia

No data on the use of low‐dose dopamine in women with severe preeclampsia who have very low urine output.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2009

Alternative magnesium sulphate regimens for women with preeclampsia and eclampsia

This review found that not enough research has been carried out to show what is the best dose for magnesium sulphate for women with preeclampsia or eclampsia, and how best to give it.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2011

Medical Encyclopedia

  • Hemolytic Anemia
    Hemolytic anemia (HEE-moh-lit-ick uh-NEE-me-uh) is a condition in which red blood cells are destroyed and removed from the bloodstream before their normal lifespan is up.
See all (1)...

Systematic Reviews in PubMed

See all (513)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...